MVM raises $233 million life sciences fund

May 3, 2016 – LONDON. MVM Life Science Partners LLP today announced the closing of a $233 million healthcare fund, MVM IV. The fund is MVM’s fourth and largest raised to date.MVM IV is investing in medical companies, principally in Europe and the United States. The fund invests broadly across the healthcare field including in technologies, therapeutics, medical devices and healthcare IT and across all stages of development from early-stage private deals to quoted companies. Investment size will generally range from $15 million up to $30 million per portfolio company.“We have had a very positive response from investors and we are delighted with the group of investors we have been able to attract,” said Dr Stephen Reeders, Managing Partner. “We believe the fund raising was helped by several factors including MVM’s compelling investment strategy, extensive track record, the strength of the team and our transatlantic presence with offices in London and Boston.”